• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial
This study evaluated whether vasomotor symptom (VMS) severity and number of moderate/severe menopausal symptoms (nMS) were associated with health outcomes, and whether calcium and vitamin D (CaD) modified the risks. Methods: The Women's Health Initiative CaD study was a double blind, randomized, placebo-controlled trial, which tested 400 IU of 25-hydroxyvitamin-D and 1,000 mg of calcium per day in women aged 50 to 79 years. This study included 20,050 women (median follow-up of 7 y). The outcomes included hip fracture, colorectal cancer, invasive breast cancer, all-cause mortality, coronary heart disease, stroke, cardi...
Source: Menopause - October 30, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Daily calcium intake in excess of 1400 mg is associated with increased all-cause and cardiovascular disease mortality in women
Commentary on: Michaëlsson K, Melhus H, Warensjö Lemming E, et al.. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ 2013;346:f228. Implications for practice and research Greater calcium intake is encouraged for bone health, but has unclear cardiovascular consequences. In a large cohort of Swedish women, total calcium intake of <600 or ≥1400 mg/day was associated with an increased risk of total mortality (TM) and cardiovascular disease mortality (CVDM). It is important to emphasise adequate dietary calcium intake in...
Source: Evidence-Based Nursing - March 14, 2014 Category: Nursing Authors: Sesso, H. D., Wang, L. Tags: Drugs: cardiovascular system, Stroke, Diet, Breast cancer, Ischaemic heart disease, Clinical diagnostic tests Primary healthcare Source Type: research